Market closed
Celsion Corporation/$IMNN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Celsion Corporation
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
Ticker
$IMNN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
25
Website
IMNN Metrics
BasicAdvanced
$13M
-
-$1.62
1.96
-
Price and volume
Market cap
$13M
Beta
1.96
52-week high
$1.18
52-week low
$0.76
Average daily volume
122K
Financial strength
Current ratio
1.673
Quick ratio
1.227
Long term debt to equity
16.185
Total debt to equity
26.843
Management effectiveness
Return on assets (TTM)
-75.60%
Return on equity (TTM)
-211.21%
Valuation
Price to book
2.97
Price to tangible book (TTM)
2.97
Price to free cash flow (TTM)
-0.53
Growth
Earnings per share change (TTM)
-25.00%
3-year earnings per share growth (CAGR)
-24.95%
IMNN News
AllArticlesVideos
IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
GlobeNewsWire·3 weeks ago
Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Celsion Corporation stock?
Celsion Corporation (IMNN) has a market cap of $13M as of April 16, 2025.
What is the P/E ratio for Celsion Corporation stock?
The price to earnings (P/E) ratio for Celsion Corporation (IMNN) stock is 0 as of April 16, 2025.
Does Celsion Corporation stock pay dividends?
No, Celsion Corporation (IMNN) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Celsion Corporation dividend payment date?
Celsion Corporation (IMNN) stock does not pay dividends to its shareholders.
What is the beta indicator for Celsion Corporation?
Celsion Corporation (IMNN) has a beta rating of 1.96. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.